Loading patent…
OwnerJonathan Schertzer, Fernando Forato Anhe +1inventors
InventorsJonathan Schertzer, Fernando Forato Anhe, Han Fang
Estimating the term…
The present application relates to methods of lowering at least one of blood glucose, liver fat, liver glycogen, insulin or insulin resistance in a mammal, for example, mammals who are obese, or have metabolic disease, fatty liver disease, pre-diabetes or type 2 diabetes. In an embodiment, a method comprises administering to a mammal a polymer comprising L-lactate monomer, or a functionally equivalent derivative or fragment thereof, which inhibits or at least reduces D-lactate transport across the intestinal barrier. Compositions useful in the methods are also provided.
A method of lowering at least one of blood glucose, liver fat, liver glycogen, insulin or insulin resistance in a mammal comprising administering to a mammal a polymer comprising L-lactate monomer, or a functionally equivalent derivative or fragment thereof, which inhibits or at least reduces D-lactate transport across the intestinal barrier.
A method of lowering at least one of blood glucose, liver fat, liver glycogen, blood insulin and insulin resistance in a mammal comprising the step of inhibiting or at least reducing D-lactate transport across the intestinal barrier of the mammal by degradation or metabolism of D-lactate.
A composition comprising a polymer comprising L-lactate monomer in combination with one or more agents that promote degradation or metabolism of D-lactate.
A composition comprising a polymer comprising L-lactate monomer linked or bound to non-biodegradable or non-digestible agent in combination with a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.